Please assess the completion status of the following clinical trial:

Trial Title: Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of 1 of the following sickle cell anemias (Hb SS):~  * Hb S/β° thalassemia~ * Hb S/β+ thalassemia~ * Hb SC disease~ * Hb SE disease~ * Hb SD disease~ * Hemoglobin SO-Arab disease~ * Hb S/hereditary persistence of fetal hemoglobin~* Meets 1 of the following criteria:~  * History of invasive pneumococcal disease~ * Stroke or CNS event lasting \> 24 hours~ * MRI changes indicative of brain parenchymal damage~ * Evidence of cerebrovascular disease by magnetic resonance angiography~ * Acute chest syndrome requiring exchange transfusion or hospitalization~ * Recurrent vaso-occlusive pain crisis (\> 2 per year for the last 2 years)~ * Stage I or II sickle lung disease~ * Sickle retinopathy~ * Osteonecrosis~ * Red cell alloimmunization (\> 2 antibodies) during long-term transfusion~ * Constellation of dactylitis in the first year of life AND a baseline hemoglobin \< 7 g/dL and leukocytosis (WBC \> 13.4/mm\^3) in the absence of infection during the second year of life~ * Pitted RBC count \> 3.5% during the first year of life~* Ineligible for or refused bone marrow transplantation from an HLA-matched sibling donor~* Partially mismatched (at least haploidentical) first-degree relative donor available~  * No minor (donor anti-recipient) ABO incompatibility if an ABO compatible donor is available~PATIENT CHARACTERISTICS:~* ECOG performance status (PS) 0-1 OR Karnofsky or Lansky PS 70-100%~* LVEF ≥ 35%~* FEV_1 and forced vital capacity ≥ 40% predicted~* Direct bilirubin \< 3.1 mg/dL~* No moderate to severe pulmonary hypertension by ECHO~* No debilitating medical or psychiatric illness that would preclude study participation~* No HIV positivity~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* No prior transfusions from donor~* No immunosuppressive agents, including steroids as antiemetics, within 24 hours after the last dose of post-transplantation cyclophosphamide

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Transplant - 200 cGy (Type: EXPERIMENTAL): Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 200. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.
- Transplant - 400 cGy (Type: EXPERIMENTAL): Conditioning regimen with anti-thymocyte globulin, fludarabine, cyclophosphamide, and total body irradiation - 400. Seizure prophylaxis with levetiracetam. Allogeneic bone marrow transplant infusion on Day 0. Graft-vs-host-disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and sirolimus.

Based on this trial design, predict the completion outcome and termination type (if applicable).